Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Divestments (2020 - 2021)

Myriad Genetics has reported Divestments over the past 2 years, most recently at $379.1 million for Q3 2021.

Quarterly Divestments rose 1679.81% to $379.1 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $379.1 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at $8.8 million for FY2024, N/A changed from the prior year.
Divestments was $379.1 million for Q3 2021 at Myriad Genetics, up from $21.3 million in the prior quarter.
Over five years, Divestments peaked at $379.1 million in Q3 2021 and troughed at -$21.3 million in Q2 2020.